Relative Intelligence · Health Care Distribution

How McKesson (MCK) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on MCK alone. It places MCK (McKesson Corporation) against 12 popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where MCK stands in the market, and of the alternatives worth a closer look.
Period covered: MCK's full trading record, from November 1994 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowMCK has run far ahead of the market, rising 24.0% over the past 3 months against 3.9% for the S&P 500 and 3.2% for the Nasdaq 100. After a 27.2% loss from March 2026 to May 2026, MCK has bounced 37.3% off the low. At a glance ↓
- Stock or market?More than an industry move: MCK rose 24.0% over the past 3 months, against 7.1% for the health care distribution ETF IHF (iShares U.S. Healthcare Providers ETF). The S&P 500 rose 3.9%. Last month cut against the tape: MCK rose 16.2% while the S&P 500 fell 0.6%.
- Past 1 to 3 yearsOver the past year, MCK rose 31.3% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (131% against 89.3%). By year ↓
- Long termMCK turned $10,000 into $68,600 over the past decade, against $42,100 in the S&P 500. MCK's 10-year return of 586% puts it ahead of 89% of the stocks worth at least $300 million with that much history. The S&P 500 returned 321%. Growth of $10,000 ↓
- In a crashThe 2015 China and oil sell-off took 30.8% off MCK, against 12.8% for the S&P 500, and more than health care distribution peers such as CVS (CVS Health, 16.9%). Crash tests ↓
- DiversificationMCK is a real diversifier: a correlation of 0.18 with the S&P 500 over 5 years and 0.19 with the total US market, less closely than 88% of stocks worth at least $300 million. Over 10 years, MCK's beta versus the S&P 500 was 0.56: 72% of the S&P 500's gains in rising months and 27% of its losses in falling ones. Market capture ↓
- Better options
- Popular alternatives
- CAH (Cardinal Health) earned more than MCK over the past 5 years with similar volatility: 42.1% a year at 24.7% volatility, against 38.7% a year at 25.0%.
- Nearby categories and themes
- LLY (Eli Lilly and Company, pharmaceuticals) was ahead of MCK in most short and long periods, though with much bigger swings (32.8% volatility against 25.0%).
- Whole market
- Nothing in the whole market did better on both counts: none of the 3,633 stocks and funds worth at least $500 million earned more than MCK with less volatility over the past 5 years.
How much would $10,000 in MCK have grown?
This chart tracks a hypothetical $10,000 investment in MCK over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of MCK over the same span and MCK's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in MCK at the end of September 1997 would have grown to $208,304 by September 2026, more than the $132,907 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of MCK, and VLO finished highest, at $1,019,941.
Choose a period
From the end of September 1997 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 291 of the 1,042 stocks and funds worth at least $500 million that traded the whole period ended ahead of MCK; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- VLO$1M+10,099% total · +17.3% a year
- NTAP$845,213+8,352% total · +16.5% a year
- UNH$772,802+7,628% total · +16.2% a year
- COR$574,137+5,641% total · +15.0% a year
- LLY$396,376+3,864% total · +13.5% a year
- MCK$208,304+1,983% total · +11.0% a year
- SPY (S&P 500)$132,907+1,229% total · +9.3% a year
- CAH$113,257+1,033% total · +8.7% a year
- CVS$97,705+877% total · +8.2% a year
- BMY$44,277+343% total · +5.3% a year
From the end of September 2021 to the end of September 2026. Hover over a fund in the key to pick out its line. 164 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of MCK; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- MPC$71,516+615% total · +48.2% a year
- PBR-A$67,821+578% total · +46.6% a year
- PBR$64,214+542% total · +45.1% a year
- LLY$52,411+424% total · +39.3% a year
- CAH$49,682+397% total · +37.8% a year
- MCK$43,941+339% total · +34.5% a year
- HIMS$39,509+295% total · +31.6% a year
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- UNH$10,283+2.8% total · +0.6% a year
- VEEV$9,905−0.9% total · −0.2% a year
MCK at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- MCK's deepest decline since it began trading in 1994 was 82.8%, from October 1998 to May 2000. It took about 11 years from the low to climb back to its old high.
- MCK is trading within 1% of its all-time high.
- Over 29 full calendar years, MCK's best was 1997, when it returned 96.3%, and its worst was 1999, when it lost 71.3%. It lost money in eight of those years.
The company
- Market value
- $120B
- Industry
- Medical - Distribution
- Price history from
- November 1994
Returns
- Past 1 year
- +31.3%total return
- Past 3 years
- +131%+32.1% a year
- Past 5 years
- +413%+38.7% a year
- Past 10 years
- +586%+21.2% a year
- Best calendar year
- +96.3%1997
- Worst calendar year
- −71.3%1999
- Losing years
- 8 of 29full calendar years
Risk
- Volatility
- 25.0%typical yearly swing, 5 years
- Sharpe ratio
- 1.44return per unit of risk, 5 years
- Worst decline ever
- −82.8%Oct 1998 to May 2000
- From its all-time high
- At its highwithin 1%
MCK against the whole market
Where MCK ranks among every stock and fund, and what across the market has done better.
How does MCK rank among all stocks?
This section ranks MCK on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how MCK stacks up against its peers, these rankings show where it stands in the market as a whole.
- On return for the risk taken (the Sharpe ratio), MCK ranks in the top 1% of the 2,893 stocks worth at least $300 million.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | MCK | Rank | Standing |
|---|---|---|---|
| 1-year return | +31.3% | 936 of 3,287 | top 28% |
| 3-year return | +131% | 702 of 3,017 | top 23% |
| 5-year return | +413% | 97 of 2,893 | top 3% |
| 10-year return | +586% | 249 of 2,202 | top 11% |
| Volatility, 5 years | 25.0% | 326 of 2,893 | top 11% |
| Sharpe ratio, 5 years | 1.44 | 4 of 2,893 | top 1% |
| Worst decline, past 10 years | −38.1% | 105 of 2,187 | top 5% |
What has beaten MCK on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). MCK sits where the dashed lines cross. Anything in the green box above and to the left earned more than MCK with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- None of the 3,633 stocks and funds worth at least $500 million earned more than MCK over the past 5 years with less volatility: nothing sits in the green region.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to MCK. 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
Is there a better investment than MCK?
Investments that beat MCK over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among MCK's popular alternatives, CAH earned more than MCK over the past 5 years with similar volatility: 42.1% a year at 24.7% volatility, against 38.7% a year at 25.0%.
- Looking beyond its popular alternatives, LLY (pharmaceuticals) was ahead of MCK in most short and long periods, though with much bigger swings (32.8% volatility against 25.0%).
- Nothing in the whole market did better on both counts: none of the 3,633 stocks and funds worth at least $500 million earned more than MCK with less volatility over the past 5 years.
How this works
The table below lists investments that beat MCK over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks MCK's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than MCK's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× MCK's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than MCK's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with MCK?lower diversifies more | Expenseper year | |||
| +38.7% | 25.0% | 1.44 | −38.1% | +586% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.18 | 0.09% | |||
| Popular alternativesbest 1 shownThe investments people most often weigh against MCK. 1 of 11 passed at least one test. | |||||||||
| On the frontierHigher return, similar volatilityHigher return in most periods | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.48 | — | ||
| Same and neighboring categories, and shared themesbest 1 shownEverything else in Health Care Distribution and the categories next to it (Medical Devices, Managed Health Care, Health Care Services, Pharmaceuticals), plus MCK's specific themes. 1 of 56 passed at least one test. | |||||||||
| Higher return in most periods | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.19 | — | ||
| The whole marketbest 6 shownEvery other stock and fund worth at least $500 million. 7 of 3,566 passed at least one test. | |||||||||
| On the frontierHigher return in most periods | +51.2% | 33.4% | 1.41 | −79.7% | +1,387% | 0.30 | — | ||
| On the frontierHigher return in most periods | +51.8% | 37.5% | 1.31 | −71.7% | +768% | 0.23 | — | ||
| Higher return in most periods | +50.3% | 37.5% | 1.28 | −75.3% | +674% | 0.23 | — | ||
| Higher return in most periods | +44.2% | 36.9% | 1.18 | −71.9% | +1,061% | 0.37 | — | ||
| Higher return in most periods | +41.8% | 31.7% | 1.27 | −90.8% | +829% | 0.37 | — | ||
| Higher return in most periods | +20.9% | 35.3% | 0.71 | −58.1% | +691% | 0.04 | — | ||
What these numbers mean for MCK
- Annual return
- MCK returned 38.7% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $51,300. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- MCK's volatility over the past 5 years was 25.0%, 1.5 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, MCK's return lands within 25.0% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- MCK's Sharpe ratio over the past 5 years was 1.44, against 0.79 for the S&P 500, so MCK earned more for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- MCK's worst fall from a peak to a low over the past 10 years was 38.1%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 38.1% fall takes a 61.6% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, MCK's monthly returns had a correlation of 0.18 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are only loosely linked, which makes it a real diversifier next to an index fund. In the table, the correlation column measures each option against MCK instead: the lower it is, the more that option would diversify a MCK holding. Guide: Correlation and diversification →
MCK against its popular alternatives
The investments people most often weigh against MCK, compared period by period and year by year.
How do MCK's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at MCK, which divides the map into what did better or worse on each measure.
- Only CAH was both more rewarding and calmer than MCK over the past 5 years, earning a higher annual return with lower volatility.
- Eight of the 11 popular alternatives earned less than MCK over the past 5 years while swinging more, the weaker corner of the map.
- Over the past 5 years, MCK returned 38.7% a year, more than the S&P 500's 12.7%, with higher volatility (25.0% against 17.1%).
Green points earned more than MCK with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| CAH Cardinal Health, Inc. | +42.1% | 24.7% |
| MCK This pageMcKesson Corporation | +38.7% | 25.0% |
| HIMS Hims & Hers Health, Inc. | +28.6% | 84.4% |
| COR Cencora, Inc. | +24.2% | 22.8% |
| HCA HCA Healthcare, Inc. | +14.1% | 30.1% |
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| BMY Bristol-Myers Squibb Company | +5.5% | 24.9% |
| CVS CVS Health Corp. | +5.3% | 30.4% |
| HSIC Henry Schein, Inc. | +1.5% | 25.4% |
| UNH UnitedHealth Group Incorporated | +1.1% | 32.1% |
| VEEV Veeva Systems Inc. | −0.1% | 39.6% |
| PFE Pfizer Inc. | −1.7% | 25.4% |
| OMCL Omnicell, Inc. | −26.1% | 51.2% |
Has MCK consistently beaten its popular alternatives?
This section compares MCK with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than MCK helps separate lasting outperformance from a single strong stretch.
- None of the 12 popular alternatives outperformed MCK in at least 3 of 5 short-term and 2 of 3 long-term timeframes. The closest was CAH.
A green cell means the alternative earned more than MCK over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| MCK McKesson Corporation (this page) | — | +16.2% | +24.0% | +20.2% | +25.5% | +31.3% | +131% | +413% | +586% | 25.0% | 1.44 | −38.1% | — | $120B | — |
| CAH Medical - DistributionCardinal Health, Inc. | 2/5 short2/3 long | +14.3% | +14.3% | +22.5% | +26.1% | +65.3% | +191% | +479% | +349% | 24.7% | 1.55 | −46.1% | — | $60B | — |
| VEEV Software - ApplicationVeeva Systems Inc. | 4/5 short1/3 long | +22.0% | +61.4% | +88.7% | +45.2% | +11.5% | +59.0% | −0.4% | +715% | 39.6% | 0.19 | −55.7% | — | $52B | — |
| HIMS Medical - Care FacilitiesHims & Hers Health, Inc. | 0/5 short1/3 long | −0.5% | −10.7% | −5.8% | −12.6% | −43.1% | +387% | +252% | — | 84.4% | 0.72 | −87.3% | — | $6.6B | — |
| BTSG Medical - Healthcare Information ServicesBrightSpring Health Services, Inc. Common Stock | 3/5 short0/3 long | +11.7% | −11.5% | +30.6% | +62.6% | +105% | — | — | — | — | — | −35.6% | — | $12B | — |
| UNH Medical - Healthcare PlansUnitedHealth Group Incorporated | 2/5 short0/3 long | +11.0% | +0.1% | +31.2% | +27.1% | +18.1% | −15.3% | +5.5% | +241% | 32.1% | 0.20 | −61.4% | — | $376B | — |
| HCA Medical - Care FacilitiesHCA Healthcare, Inc. | 1/5 short0/3 long | +9.3% | +26.0% | −2.2% | −0.5% | +8.3% | +97.6% | +93.6% | +513% | 30.1% | 0.59 | −54.7% | — | $101B | — |
| BMY Drug Manufacturers - GeneralBristol-Myers Squibb Company | 1/5 short0/3 long | −0.5% | +3.6% | +6.6% | +19.1% | +47.8% | +25.8% | +30.6% | +74.8% | 24.9% | 0.34 | −47.7% | — | $126B | — |
| CVS Medical - Healthcare PlansCVS Health Corp. | 1/5 short0/3 long | +8.2% | −11.4% | +25.6% | +21.0% | +18.5% | +52.5% | +29.2% | +47.0% | 30.4% | 0.32 | −56.8% | — | $121B | — |
| HSIC Medical - DistributionHenry Schein, Inc. | 1/5 short0/3 long | −0.6% | −1.8% | +7.0% | +10.2% | +32.5% | +24.0% | +7.9% | +41.3% | 25.4% | 0.19 | −41.4% | — | $9.4B | — |
| COR Medical - DistributionCencora, Inc. | 0/5 short0/3 long | +8.5% | +13.1% | +6.7% | +1.9% | +5.7% | +86.5% | +195% | +406% | 22.8% | 1.07 | −32.4% | — | $66B | — |
| PFE Drug Manufacturers - GeneralPfizer Inc. | 0/5 short0/3 long | +8.5% | +23.8% | +13.2% | +25.7% | +30.5% | +19.2% | −8.3% | +55.0% | 25.4% | 0.06 | −58.9% | — | $172B | — |
| OMCL Medical - Healthcare Information ServicesOmnicell, Inc. | 0/5 short0/3 long | +12.5% | −19.3% | −3.5% | −19.2% | +20.8% | −7.9% | −77.9% | +1.5% | 51.2% | -0.34 | −86.6% | — | $1.7B | — |
How did MCK do year by year?
This table shows each investment's total return in every full calendar year since 1997, along with where MCK ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with MCK and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- None of the 11 popular alternatives came out ahead of MCK in most of the years they have in common.
- Ranked against its popular alternatives each year, MCK finished in the top quarter in eight of 29 years and in the bottom quarter in three. In 2025, it ranked 6 of 13.
- MCK finished ahead of the S&P 500 in 15 of its 29 full calendar years.
Newest year first. Green marks a year in which the fund came out ahead of MCK; gray means the two finished within a fraction of a point. The rank row places MCK among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of MCK | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCK This pageMcKesson Corporation | — | +44.5% | +23.7% | +24.1% | +51.8% | +44.2% | +27.1% | +26.7% | −28.4% | +12.0% | −28.3% | −4.5% | +29.3% | +67.7% | +25.6% | +11.8% | +13.8% | +62.9% | −40.4% | +29.7% | −1.2% | +64.9% | −1.4% | +19.9% | −27.2% | +4.9% | +61.2% | −71.3% | +46.9% | +96.3% |
| Rank among alternatives | Top quarter in 8 of 29 | 6 of 13 | 2 of 12 | 4 of 12 | 2 of 12 | 6 of 12 | 4 of 12 | 4 of 11 | 11 of 11 | 7 of 11 | 11 of 11 | 9 of 11 | 6 of 11 | 3 of 10 | 2 of 10 | 6 of 9 | 6 of 9 | 1 of 9 | 7 of 9 | 2 of 9 | 7 of 9 | 1 of 9 | 5 of 9 | 6 of 9 | 7 of 9 | 4 of 8 | 5 of 8 | 8 of 8 | 4 of 8 | 1 of 8 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 14 of 29 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% | −9.8% | +20.4% | +28.7% | +33.5% |
| CAH Cardinal Health, Inc. | 11 of 29 | +76.3% | +19.0% | +34.1% | +54.1% | −0.4% | +10.1% | +18.0% | −24.5% | −12.7% | −17.5% | +12.6% | +23.0% | +66.0% | +3.8% | +8.1% | +21.4% | −4.4% | −39.6% | −9.8% | −5.8% | +18.7% | −4.7% | +3.5% | −8.3% | −2.5% | +108% | −36.8% | +51.7% | +29.1% |
| VEEV Veeva Systems Inc. | 6 of 12 | +6.2% | +9.2% | +19.3% | −36.8% | −6.2% | +93.5% | +57.5% | +61.6% | +35.8% | +41.1% | +9.2% | −17.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| HIMS Hims & Hers Health, Inc. | 3 of 6 | +34.3% | +172% | +38.8% | −2.1% | −55.1% | +47.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BTSG BrightSpring Health Services, Inc. Common Stock | 1 of 1 | +120% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| UNH UnitedHealth Group Incorporated | 13 of 29 | −33.1% | −2.4% | +0.8% | +6.9% | +45.2% | +21.3% | +20.0% | +14.5% | +39.8% | +38.4% | +18.3% | +36.5% | +41.0% | +8.6% | +42.2% | +19.9% | +14.8% | −54.3% | +8.3% | −13.5% | +41.2% | +51.4% | +39.4% | +18.1% | +15.3% | +131% | +23.5% | −13.4% | +10.3% |
| HCA HCA Healthcare, Inc. | 7 of 14 | +56.7% | +11.8% | +13.8% | −5.6% | +57.6% | +11.6% | +20.2% | +43.4% | +18.7% | +9.4% | −7.8% | +53.8% | +58.1% | +70.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BMY Bristol-Myers Squibb Company | 10 of 29 | +0.1% | +15.8% | −26.1% | +19.0% | +2.9% | +0.4% | +27.7% | −12.9% | +7.7% | −13.5% | +19.3% | +14.2% | +70.0% | −3.8% | +39.4% | +8.8% | +14.8% | −6.1% | +4.8% | +19.9% | −6.2% | −7.2% | +29.1% | −52.4% | −26.2% | +17.1% | −2.8% | +42.9% | +77.1% |
| CVS CVS Health Corp. | 14 of 29 | +84.3% | −40.8% | −12.6% | −7.6% | +54.9% | −5.1% | +17.3% | −7.0% | −5.8% | −17.8% | +2.9% | +36.5% | +50.4% | +20.3% | +19.0% | +9.1% | +13.2% | −27.2% | +29.4% | +17.7% | +17.8% | +25.7% | +45.7% | −14.9% | −50.4% | +51.1% | −27.1% | +72.6% | +55.5% |
| HSIC Henry Schein, Inc. | 10 of 29 | +9.2% | −8.6% | −5.2% | +3.0% | +16.0% | +0.2% | +8.3% | +12.3% | −7.9% | −4.1% | +16.2% | +19.1% | +42.1% | +24.8% | +5.0% | +16.7% | +43.4% | −40.2% | +25.4% | +12.3% | +25.4% | +3.0% | +50.2% | +21.5% | +6.9% | +160% | −70.2% | +27.8% | +1.8% |
| COR Cencora, Inc. | 14 of 29 | +51.5% | +10.4% | +25.3% | +26.3% | +38.0% | +17.0% | +18.2% | −16.6% | +20.6% | −23.3% | +16.9% | +29.9% | +65.3% | +17.9% | +10.3% | +32.4% | +48.0% | −19.8% | +3.3% | +8.9% | +41.4% | +2.5% | +5.6% | −14.5% | +25.8% | +233% | −53.3% | +11.7% | +20.8% |
| PFE Pfizer Inc. | 11 of 29 | +0.6% | −2.2% | −41.3% | −10.4% | +66.7% | +3.4% | −6.7% | +25.1% | +16.1% | +4.4% | +7.3% | +5.4% | +26.5% | +20.6% | +28.8% | +0.6% | +8.1% | −16.9% | −8.2% | +15.3% | −10.6% | −22.3% | +17.7% | −22.2% | −12.5% | +43.0% | −21.5% | +68.8% | +82.0% |
| OMCL Omnicell, Inc. | 12 of 24 | +1.8% | +18.3% | −25.4% | −72.1% | +50.3% | +46.9% | +33.4% | +26.3% | +43.1% | +9.1% | −6.2% | +29.7% | +71.7% | −10.0% | +14.3% | +23.6% | −4.3% | −54.7% | +44.5% | +55.9% | +8.6% | −32.1% | +511% | −70.2% | — | — | — | — | — |
Risk and diversification
How MCK has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were MCK's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents MCK's five deepest drawdowns since it began trading in 1994, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- In all five of MCK's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: MCK fell 82.8% from October 1998 to May 2000, while the S&P 500 rose 42.3%.
- The slowest recovery came after MCK fell 82.8% from October 1998 to May 2000; it did not regain that peak until May 2011, 11 years later.
Green means MCK fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | MCK fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| Dot-com bust | −82.8% | +42.3% | Oct 1998 | May 2000 | 19 months | May 2011 | 11 years |
| 2015 China and oil sell-off | −54.1% | +18.6% | May 2015 | Dec 2018 | 3.6 years | Dec 2021 | 3 years |
| No named crash | −27.2% | +9.0% | Mar 2026 | May 2026 | 2 months | Oct 2026 | 5 months |
| No named crash | −25.7% | +0.2% | Mar 1996 | Jul 1996 | 4 months | Nov 1996 | 4 months |
| No named crash | −23.9% | +7.7% | Aug 2024 | Sep 2024 | 1 month | Feb 2025 | 5 months |
How did MCK do in stock market crashes?
This section measures how far MCK, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
- Among its popular alternatives, BMY held up best, falling less than MCK in six of the ten crashes they both traded through.
- MCK fell less than the S&P 500 in five of the ten crashes it has traded through. The clearest case was the 2022 bear market, when MCK fell 10.5% and the S&P 500 fell 24.5%.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than MCK.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCK This pageMcKesson Corporation | — | −0.9% | −10.5% | −32.1% | −20.7% | −6.5% | −30.8% | −14.2% | −3.5% | −57.7% | −39.4% |
| SPY S&P 500State Street SPDR S&P 500 ETF | 4 of 10 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| CAH Cardinal Health, Inc. | 4 of 10 | −3.5% | −21.0% | −32.1% | −25.5% | −4.6% | −15.9% | −17.5% | −1.8% | −57.9% | −36.1% |
| VEEV Veeva Systems Inc. | 2 of 6 | −4.6% | −40.0% | −26.7% | −26.5% | −9.5% | −28.9% | — | — | — | — |
| HIMS Hims & Hers Health, Inc. | 1 of 3 | −10.0% | −52.1% | −7.0% | — | — | — | — | — | — | — |
| UNH UnitedHealth Group Incorporated | 4 of 10 | −1.8% | −16.9% | −35.9% | −18.6% | −6.7% | −12.4% | −20.7% | −0.8% | −72.4% | −19.8% |
| HCA HCA Healthcare, Inc. | 1 of 7 | −2.2% | −39.5% | −54.4% | −20.6% | −3.8% | −31.3% | −49.0% | — | — | — |
| BMY Bristol-Myers Squibb Company | 6 of 10 | −2.3% | −16.0% | −29.4% | −22.9% | −4.1% | −16.3% | −10.5% | 0.0% | −39.2% | −69.5% |
| CVS CVS Health Corp. | 4 of 10 | −4.4% | −19.9% | −27.3% | −22.1% | −9.2% | −16.9% | −14.2% | −1.1% | −45.3% | −62.4% |
| HSIC Henry Schein, Inc. | 5 of 10 | −1.0% | −28.5% | −41.4% | −17.7% | −4.7% | −12.8% | −18.3% | −3.0% | −47.8% | −25.6% |
| COR Cencora, Inc. | 5 of 10 | −2.3% | −17.8% | −23.8% | −24.2% | −7.1% | −21.4% | −14.5% | −2.8% | −41.9% | −29.7% |
| PFE Pfizer Inc. | 5 of 10 | −1.8% | −24.6% | −21.8% | −12.3% | −8.1% | −18.2% | −16.1% | −1.8% | −49.8% | −46.0% |
| OMCL Omnicell, Inc. | 2 of 9 | −7.7% | −58.3% | −37.4% | −26.2% | −12.8% | −27.0% | −23.7% | −2.1% | −77.4% | — |
How closely does MCK move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares MCK with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- None of the ten popular alternatives with the same record had a higher capture ratio (upside capture divided by downside capture) than MCK's 2.71.
- Over the past 10 years, MCK captured 72% of the S&P 500's gains in rising months and 27% of its losses in falling months, with a beta of 0.56. That is a defensive profile: it gave up some of the market's upside in exchange for smaller losses.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than MCK's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| MCK This pageMcKesson Corporation | 72% | 27% | 2.71 | 0.56 |
| CAH Cardinal Health, Inc. | 71% | 51% | 1.40 | 0.75 |
| COR Cencora, Inc. | 80% | 58% | 1.39 | 0.56 |
| VEEV Veeva Systems Inc. | 113% | 89% | 1.26 | 0.87 |
| UNH UnitedHealth Group Incorporated | 81% | 82% | 0.98 | 0.70 |
| HCA HCA Healthcare, Inc. | 135% | 140% | 0.97 | 1.37 |
| BMY Bristol-Myers Squibb Company | 55% | 75% | 0.73 | 0.41 |
| PFE Pfizer Inc. | 52% | 81% | 0.65 | 0.54 |
| CVS CVS Health Corp. | 59% | 99% | 0.60 | 0.70 |
| HSIC Henry Schein, Inc. | 72% | 124% | 0.59 | 0.85 |
| OMCL Omnicell, Inc. | 93% | 187% | 0.50 | 1.03 |
What diversifies MCK?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with MCK's. Because such investments tend not to fall at the same time, pairing MCK with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in MCK into SMH would have cut the portfolio's volatility by 18% over the past 5 years and raised its annual return (+34.4% for MCK alone, +37.0% for the mix).
- Among large ETFs, LVHI, DXJ and HDV have moved largely independently of MCK over the past 5 years, with correlations of 0.43 or lower, and each still earned a positive 5-year return.
- FIX made money in five of the eight calendar years in which MCK lost money.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which MCK lost money. The last two columns show a portfolio that is 80% MCK and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2018 | 2016 | 2015 | 2008 | 2006 | 2004 | 2002 | 1999 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCK McKesson Corporation (this page) | 1.00 | +413% | 1.44 | −28.4% | −28.3% | −4.5% | −40.4% | −1.2% | −1.4% | −27.2% | −71.3% | 25.2% | +34.4% |
| LVHI InternationalFranklin International Low Volatility High Dividend Index ETF | 0.34 | +119% | 1.48 | −5.2% | — | — | — | — | — | — | — | 20.9% | +31.3% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.31 | +225% | 1.34 | −19.8% | +1.1% | +7.7% | −20.8% | — | — | — | — | 21.1% | +33.5% |
| HDV Dividend & IncomeiShares Core High Dividend ETF | 0.43 | +83.3% | 1.00 | −3.0% | +15.9% | −0.3% | — | — | — | — | — | 21.6% | +30.2% |
| MLPX EnergyGlobal X - MLP & Energy Infrastructure ETF | 0.48 | +135% | 0.97 | −15.5% | +36.3% | −35.3% | — | — | — | — | — | 22.2% | +32.0% |
| SMH TechnologyVanEck Semiconductor ETF | -0.08 | +323% | 0.97 | −9.1% | +35.6% | −0.3% | −44.7% | −6.7% | −19.3% | −47.0% | — | 20.8% | +37.0% |
| DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF | 0.23 | +85.0% | 0.96 | −9.5% | +6.3% | +4.1% | — | — | — | — | — | 20.8% | +30.6% |
| GLD CommoditiesSPDR Gold Shares | 0.20 | +126% | 0.96 | −1.9% | +8.0% | −10.7% | +4.9% | +22.6% | — | — | — | 21.1% | +31.8% |
| SPMO Broad MarketInvesco S&P 500 Momentum ETF | 0.06 | +136% | 0.93 | −0.9% | +7.4% | — | — | — | — | — | — | 20.8% | +32.8% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2018 | 2016 | 2015 | 2008 | 2006 | 2004 | 2002 | 1999 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCK McKesson Corporation (this page) | 1.00 | +413% | 1.44 | −28.4% | −28.3% | −4.5% | −40.4% | −1.2% | −1.4% | −27.2% | −71.3% | 25.2% | +34.4% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.48 | +479% | 1.55 | −24.5% | −17.5% | +12.6% | −39.6% | −5.8% | −4.7% | −8.3% | −36.8% | 23.2% | +35.8% |
| CLS Hardware, Equipment & PartsCelestica Inc. | 0.08 | +3,143% | 1.47 | −16.3% | +7.4% | −6.0% | −20.5% | −26.0% | −6.4% | −65.1% | +350% | 24.2% | +51.0% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.16 | +1,636% | 1.46 | +0.8% | +18.3% | +67.7% | −15.2% | +38.9% | +40.0% | −9.4% | −58.7% | 23.4% | +46.3% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.30 | +690% | 1.41 | −8.2% | +0.7% | +17.4% | — | — | — | — | — | 23.0% | +38.4% |
| HWM Aerospace & DefenseHowmet Aerospace Inc. | 0.46 | +594% | 1.36 | −37.5% | −11.5% | −36.3% | −67.4% | +5.5% | −14.1% | −33.1% | +133% | 24.2% | +38.3% |
Common questions
What was MCK's worst drawdown?
MCK's deepest decline since it began trading in 1994 was 82.8%, from October 1998 to May 2000. It took about 11 years from the low to climb back to its old high.
What were MCK's best and worst years?
Over 29 full calendar years, MCK's best year was 1997, when it returned 96.3%. Its worst was 1999, with a return of -71.3%.
Is there a better investment than MCK?
Among MCK's popular alternatives, CAH earned more than MCK over the past 5 years with similar volatility: 42.1% a year at 24.7% volatility, against 38.7% a year at 25.0%. Looking beyond its popular alternatives, LLY (pharmaceuticals) was ahead of MCK in most short and long periods, though with much bigger swings (32.8% volatility against 25.0%).
Is MCK more volatile than the S&P 500?
Yes. MCK's volatility over the past 5 years was 25.0%, 1.5 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, MCK's return lands within 25.0% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is MCK's Sharpe ratio?
MCK's Sharpe ratio over the past 5 years was 1.44, against 0.79 for the S&P 500, so MCK earned more for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is MCK with the S&P 500?
Over the past 5 years, MCK's monthly returns had a correlation of 0.18 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are only loosely linked, which makes it a real diversifier next to an index fund. In the table, the correlation column measures each option against MCK instead: the lower it is, the more that option would diversify a MCK holding.
What are the best alternatives to MCK?
None of the 12 popular alternatives we compared outperformed MCK in at least 3 of 5 short-term and 2 of 3 long-term timeframes, which says more about MCK's strength than about its alternatives.
Did MCK outperform the S&P 500?
MCK finished ahead of the S&P 500 (SPY) in 15 of 29 full calendar years. In 2025, it returned +44.5%, against +17.7% for the index.
How did MCK do in stock market crashes?
MCK fell less than the S&P 500 (SPY) in five of the ten major crashes it has traded through, and further in four. The clearest case was the 2022 bear market, when MCK fell 10.5% and the S&P 500 fell 24.5%.
What diversifies MCK?
These had a low correlation with MCK over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.34), DXJ (correlation 0.31) and HDV (correlation 0.43); among large stocks, CAH (correlation 0.48), CLS (correlation 0.08) and FIX (correlation 0.16). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than MCK's. Returns within 0.5 points or 3% of MCK's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.
More research
Popular alternatives to MCK
CAHCardinal Health
VEEVVeeva Systems
UNHUnitedHealth Group
HCAHCA Healthcare
BMYBristol-Myers Squibb
CVSCVS Health
CORCencora
PFEPfizer